PatentJul 15, 2026, 09:47 AM
NewcelX Granted Brazil Patent for NCEL-101 in Type 1 Diabetes
AI Summary
NewcelX Ltd. announced that the Brazilian Patent and Trademark Office has issued a patent for its innovative cell selection and enrichment technology, protecting the manufacturing process of its lead clinical compound, NCEL-101, until November 2036. This patent expands the company's global intellectual property portfolio, strengthening its position in the strategically important Brazilian Type 1 Diabetes market, which has approximately 500,000 patients. The grant follows a successful FDA Type B Pre-IND meeting for NCEL-101, paving the way for clinical trials.
Key Highlights
- NewcelX granted Patent Number BR 112018010946-0 in Brazil for NCEL-101.
- The patent protects the manufacturing process of NCEL-101 until November 2036.
- Brazil is a key market with approximately 500,000 people living with Type 1 Diabetes (T1D).
- T1D prevalence in Brazil is growing at an estimated annual rate of 4.4%.
- The patent follows a successful FDA Type B Pre-IND meeting for NCEL-101.
- NCEL-101 features ~60% Beta cells co-expressing insulin and NKX6.1.
- NCEL-101 demonstrates 99.98% endocrine lineage and over 96% non-proliferative cells.
Price Impact
More from NCEL